Last reviewed · How we verify
BIBW 2992 high dose 6 day — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BIBW 2992 high dose 6 day (BIBW 2992 high dose 6 day) — Boehringer Ingelheim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BIBW 2992 high dose 6 day TARGET | BIBW 2992 high dose 6 day | Boehringer Ingelheim | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BIBW 2992 high dose 6 day CI watch — RSS
- BIBW 2992 high dose 6 day CI watch — Atom
- BIBW 2992 high dose 6 day CI watch — JSON
- BIBW 2992 high dose 6 day alone — RSS
Cite this brief
Drug Landscape (2026). BIBW 2992 high dose 6 day — Competitive Intelligence Brief. https://druglandscape.com/ci/bibw-2992-high-dose-6-day. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab